PT-141 for Libido

What is PT-141 for libido and how does it work?

PT-141 (bremelanotide) is a melanocortin receptor agonist that targets sexual desire through the central nervous system, not through the vascular system. Most well-known sexual-function drugs work on blood flow. PT-141 works upstream of that, activating melanocortin-4 receptors (MC4R) in brain regions tied to sexual motivation (Kingsberg et al., 2019). Because the mechanism is central, researchers have studied it for low desire rather than for a purely mechanical response.

In practical terms, that means the studied target was desire and the distress low desire causes, not erection hardness or lubrication alone. The RECONNECT trials were built around that idea and measured desire and distress as their main outcomes (Kingsberg et al., 2019).

What did the RECONNECT phase 3 trials report?

The RECONNECT program met its two co-primary endpoints: it improved sexual desire scores and reduced desire-related distress compared with placebo. The trials enrolled about 1,267 premenopausal women with acquired, generalized HSDD, a condition defined by persistent low sexual desire that causes personal distress (Kingsberg et al., 2019). Participants used the study drug on an as-needed basis before anticipated sexual activity rather than on a daily schedule.

The endpoint improvements were statistically significant against placebo, which is what supported the later FDA approval of the compound as Vyleesi for this specific population (Kingsberg et al., 2019). The trials studied premenopausal women only, so the data do not extend to postmenopausal women or to men without further study.

What are the reported side effects?

Nausea was the most common reported effect, seen in roughly 40 percent of participants across the bremelanotide program (Kingsberg et al., 2019). Other reported effects in the trials included flushing and headache. Some participants also reported transient increases in blood pressure and, less commonly, temporary skin darkening with repeated use, consistent with melanocortin-pathway activity (Kingsberg et al., 2019).

Because nausea was frequent, it was also a common reason participants discontinued in the studies. These are reported trial observations, not a prediction of what any individual will experience.

What dose did the research report?

Research reported an as-needed subcutaneous dose of 1.75 mg, used before anticipated activity, not on a fixed daily schedule. The table below summarizes what the published trials describe. It is a record of what studies reported, not a recommendation. Any personal dose belongs to a conversation with a qualified clinician.

Do not read this table as instructions. It describes the trial design so you can understand the published evidence. A clinician who knows your health history is the right source for any decision about use.

How is PT-141 different from erectile-function drugs?

The core difference is where the compound acts: PT-141 works on central desire pathways, while common erectile drugs act on blood flow. Vascular drugs help the physical response but do not directly address desire. PT-141 was studied for the desire side, which is why the RECONNECT endpoints measured desire and distress rather than physical performance (Kingsberg et al., 2019). The two approaches target different parts of the sexual response.

Is PT-141 approved and who was it studied in?

Yes, it is FDA-approved as Vyleesi, and the pivotal data were in premenopausal women with acquired, generalized HSDD. The RECONNECT trials that supported approval enrolled about 1,267 women in that group (Kingsberg et al., 2019). Approval is specific to that population. Evidence outside it, including in men, is more limited and does not carry the same phase 3 support.